Inflammatory Breast Cancer Clinical Trials
The Morgan Welch Inflammatory Breast Cancer (IBC) Research Program conducts treatment-based studies and a wide variety of lab-based studies to understand this disease better. Additional IBC clinical trials can be found at .
If you would like more information about becoming involved with our clinical trials in general, you may email our program at IBCP@MDAnderson.org.
IBC Registry
: Inflammatory breast cancer registry (Also open at select IBC Connect sites, through UT MD Anderson's cancer network)
Contact Info:
Research Investigator: , VValero@MDAnderson.org
Research Trial Lead: Angela Alexander, Ph.D., AAlexand@MDAnderson.org
The IBC Registry is our master biospecimen banking study that allows us to collect data, blood and tissue samples to support the entire research program at UT MD Anderson and beyond. All patients with diagnosed or suspected IBC are eligible to be enrolled, regardless of treatment choices.
Trials for Newly Diagnosed IBC
: TRUDI: A Phase 2 study of neoadjuvant trastuzumab deruxtecan and durvalumab for stage III, HER2-expressing inflammatory breast cancer
Contact Info:
Research Investigator: , RLayman@MDAnderson.org
Research Trial Lead: Angela Marx, R.N., ANMarx@MDAnderson.org
: S2206: Phase 3 trial of neoadjuvant durvalumab (NSC 778709) plus chemotherapy versus chemotherapy alone for adults with MammaPrint Ultrahigh (MP2) Hormone Receptor (HR) positive/Human Epidermal Growth Factor Receptor (HER2) negative stage 2-3 breast cancer
Contact Info:
Research Investigator: , RLayman@MDAnderson.org
Research Trial Lead: Angela Alexander, Ph.D., AAlexand@MDAnderson.org
Trials for Patients after Initial Treatment and Surgery are Completed
No adjuvant trials are currently enrolling.
Trials Focusing on Breast Surgery or Radiation
No local therapy trials are currently enrolling.
Trials for Metastatic/Recurrent IBC
: A Phase 1b study of novel combination of low dose oral cyclophosphamide to potentiate axatilimab (immunotherapy) + retifanlimab (immunotherapy)
Contact Info:
Research Investigator: , BLim@MDAnderson.org
Research Trial Lead: Angela Alexander, Ph.D., AAlexand@MDAnderson.org
: A Phase 1 study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary antitumor activity of BGB-21447 (a BCL-2 inhibitor) combinations for patients with HR+/HER2- metastatic breast cancer
Contact Info:
Research Investigator: , BLim@MDAnderson.org
Research Trial Lead: Angela Alexander, Ph.D., AAlexand@MDAnderson.org
Non-Treatment Trials (Various Eligibility)
Data collection and laboratory-based research using patient samples (tissue and/or blood)
Protocol 2019-1028: Delineating the microenvironment of aggressive breast cancer with single cell and spatial genomics in the context of metastasis and treatment response
Contact Info:
Research Investigator: , BLim@MDAnderson.org
Research Trial Lead: Angela Alexander, Ph.D., AAlexand@MDAnderson.org
Protocol 2019-1242: Establishment of humanized PDX and organoid models of inflammatory breast cancer
Contact Info:
Research Investigator: , ANasrazadani1@MDAnderson.org
Research Trial Lead: Angela Alexander, Ph.D., AAlexand@MDAnderson.org
Protocol 2023-0889: Molecular profiling and immune profiling of inflammatory breast cancer: Analysis of BostonGene TumorPortrait results
Contact Info:
Research Investigator: , ANasrazadani1@MDAnderson.org
Research Trial Lead: Angela Alexander, Ph.D., AAlexand@MDAnderson.org
Protocol 2022-1024: Umbrella protocol for ARTIDIS nanomechanical generated measurements in solid tumors (IBC cohort)
Contact Info:
Overall Research Investigator: , EKoay@MDAnderson.org
IBC Research Investigator: , WWoodward@MDAnderson.org
Research Trial Leads: Angela Alexander, Ph.D., AAlexand@MDAnderson.org; Sanda Tin, B.M.E.D., M.D., STin@MDAnderson.org
Protocol 2025-0415: IBC Clear: Multi-center MRD registry for inflammatory breast cancer
Contact Info:
Research Investigator: , SSaleem@MDAnderson.org
Research Trial Lead: Angela Alexander, Ph.D., AAlexand@MDAnderson.org
Give Now
Research Areas
Find out about the four types of research taking place at UT?MD Anderson.